Tianjin PuYing Biotechnology Co., Ltd.

To evaluate the efficacy and safety of recombinant human serum albumin/granulocyte stimulating factor fusion protein for injection in preventing chemotherapy-induced neutropenia and to provide a basis for safe and effective dosing regimens in phase III clinical trials.

The research plan of this Phase I clinical trial aims to obtain data on the drug's safety, tolerability, initial effective dose and pharmacokinetics, and provide a scientific basis for the conduct of Phase II clinical research.

(1) To evaluate the safety and tolerability of rHSA/EPO in healthy subjects; (2) To investigate the pharmacokinetic properties of rHSA/EPO in healthy subjects and obtain preliminary pharmacokinetic parameters.